If you are interested in speaking with The Conafay Group about crafting a proposal, please contact Steve Wasserman (ssw3an).
The Department of Defense (DoD) has announced its FY19 funding opportunities in its Amyotrophic Lateral Sclerosis Research Program (ALSRP). Detailed descriptions of the funding opportunity, evaluation criteria, and submission requirements can be found in the Program Announcements. The Program Announcements are available electronically for downloading from the Grants.gov website (http://www.grants.gov) or the ALSRP web site (https://cdmrp.army.mil/funding/alsrp).
For both of these awards, pre-applications are due on March 22, 2019. Invited full applications are due July 25, 2019.
Therapeutic Idea Award (https://cdmrp.army.mil/funding/pa/FY19-ALSRP-TIA.pdf)
- Independent investigators at all academic levels (or equivalent) are eligible to be named as PI.
- The Therapeutic Idea Award is designed to promote new ideas aimed at drug or treatment
discovery that are still in the early stages of development. Projects that focus primarily on
investigating the pathophysiology of ALS are not within the scope of this Funding Opportunity. - Development and/or modification of preclinical model systems or the application of high throughput screens to define or assess lead compounds for ALS treatment are of interest.
- Development of methods to adequately measure target binding and proximal downstream effects
(target engagement) and the potential for undesirable activities at related but unintended targets
(selectivity) are also encouraged. While the inclusion of preliminary data is not prohibited, the
strength of the application should not rely on preliminary data, but on the innovative approach. - Identification of treatment approaches using biological correlates of disease activity and
progression in pre-existing, de-identified human specimens from well-characterized, adequately
controlled, and sufficiently powered patient cohorts is encouraged. - The anticipated direct costs budgeted for the entire period of performance for an FY19 ALSRP
Therapeutic Idea Award will not exceed $500,000. DoD has set aside approximately $4M to fund five of these awards.
Therapeutic Development Award (https://cdmrp.army.mil/funding/pa/FY19-ALSRP-TDA.pdf)
- Independent investigators at all academic levels (or equivalent) are eligible to be named as PI.
- Applicants with limited ALS experience are strongly encouraged to collaborate with
those having substantial expertise in ALS research and/or ALS model systems. - Applications supported by this award must begin with lead compounds in hand and must include
preliminary data relevant to the phase of development, such as: Proof of identity and purity; Selectivity for the intended target over closely related targets; Availability of primary and secondary in vitro bioactivity assays for optimization or structure-activity relationship studies; or Availability of proof-of-concept efficacy data in appropriate preclinical model systems of
ALS, including whole animal and cellular model systems, or informative clinical data from a
related human disease. - Therapeutically Relevant Marker Option: The FY19 ALSRP Therapeutic Development
Award Therapeutically Relevant Marker Option encourages applicants to develop a specific
marker(s) in parallel with the advanced therapeutic development effort. - The anticipated direct costs budgeted for the entire period of performance for an FY19 ALSRP
Therapeutic Development Award will not exceed $1,000,000. The anticipated direct costs
budgeted for the entire period of performance for an FY19 ALSRP Therapeutic Development
Award with the Therapeutically Relevant Marker Option will not exceed $1,250,000. DoD has set aside approximately $4.8M to fund three of these awards.
All CDMRP funding opportunities, both recently and previously released, are available on the CDMRP website (http://cdmrp.army.mil).
Submission is a two-step process requiring both pre-application submission and full application submission. All pre-applications must be submitted through eBRAP (https://eBRAP.org/). Full applications from extramural organizations (non-DoD organizations) must be submitted through Grants.gov (http://www.grants.gov/). Intramural DoD organizations may submit full applications to either eBRAP or Grants.gov. Refer to the General Application Instructions, Section II.A. for registration and submission requirements for eBRAP and Grants.gov. For detailed information on the submission process, refer to Section II.D. of the Program Announcement/Funding Opportunity.
eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.
Filed Under: Funding Opportunities